

# Hiroyuki Yasuda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2378631/hiroyuki-yasuda-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84

papers

2,488

citations

26

h-index

48

g-index

87

ext. papers

3,022

ext. citations

5.4

avg. IF

4.72

L-index

#	Paper	IF	Citations
84	Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009542	7.6	8
83	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 162, 140-146	5.9	6
82	Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study. <i>Palliative Medicine</i> , <b>2021</b> , 35, 943-951	5.5	1
81	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , <b>2021</b> , 35, 109218	10.6	15
80	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 3916-3929	10.1	2
79	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. <i>Biochemical and Biophysical Research Communications</i> , <b>2021</b> , 534, 1-7	3.4	2
78	SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 317-328	6.6	1
77	HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 631-642	3.2	4
76	Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress. <i>Oncologist</i> , <b>2021</b> , 26, e2265-e2273	5.7	1
75	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. <i>Japanese Journal of Lung Cancer</i> , <b>2021</b> , 61, 911-918	0.1	
74	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. <i>Cell</i> , <b>2020</b> , 183, 1420-1435.e21	56.2	39
73	Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	2
72	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 549-559	6.6	20
71	Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells. <i>Cancer Science</i> , <b>2020</b> , 111, 3793-3801	6.9	2
70	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1065-1071	3.5	1
69	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Mutations. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2233-2243	6.6	24
68	Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. <i>Journal of Pathology</i> , <b>2019</b> , 249, 193-205	9.4	27

67	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10025-10030	11.5	30
66	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1593-1601	6.1	2
65	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , <b>2019</b> , 127, 146-152	5.9	29
64	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in -Mutated Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 740-750	6.1	18
63	Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. <i>Lung Cancer</i> , <b>2018</b> , 119, 25-35	5.9	16
62	Intermittent Exposure to Cigarette Smoke Increases Lung Tumors and the Severity of Emphysema More than Continuous Exposure. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2018</b> , 59, 179-188	5.7	11
61	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e349-e358	4.9	36
60	The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 503, 1330-1334	3.4	13
59	Comparison of detection methods of T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 3335-3343	4.4	13
58	Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer. <i>Internal Medicine</i> , <b>2018</b> , 57, 2383-2387	1.1	2
57	Clinical characterization and in silico drug sensitivity prediction model of rare EGFR mutations in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21221-e21221	2.2	
56	Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers. <i>Oncologist</i> , <b>2018</b> , 23, 1218-1229	5.7	15
55	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2018</b> , 5, 172-177	2.2	4
54	EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib. <i>Internal Medicine</i> , <b>2018</b> , 57, 1007-1010	1.1	5
53	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6548-6555	12.9	31
52	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , <b>2017</b> , 77, 2078-2089	10.1	82
51	Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung. <i>Respiratory Research</i> , <b>2017</b> , 18, 69	7.3	7
50	Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. <i>Lung Cancer</i> , <b>2017</b> , 109, 45-51	5.9	26

49	Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001). <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 6, 409-414	1.6	8
48	Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. <i>Journal of Dermatology</i> , <b>2017</b> , 44, 818-821	1.6	12
47	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , <b>2017</b> , 14, 3559-3565	2.6	7
46	Sternoclavicular joint osteomyelitis extending to lung abscess complicated by Staphylococcal infective endocarditis. <i>IDCases</i> , <b>2017</b> , 9, 36-37	2	
45	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 106-114	6.6	36
44	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 31-38	3.8	16
43	Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports. <i>Medicine (United States)</i> , <b>2017</b> , 96, e9081	1.8	2
42	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1774-1785	4.5	23
41	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 105479-105491	3.3	27
40	The efficacy and safety of nivolumab in advanced non-small cell lung cancer in clinical practice in Japan: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20577-e20577	2.2	
39	Activation of EGFR Bypass Signaling by TGF $\beta$ Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 162-71	6.1	38
38	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , <b>2016</b> , 2016, 1075641	0.9	20
37	Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. <i>Molecular and Clinical Oncology</i> , <b>2016</b> , 5, 488-490	1.6	5
36	A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 513-9	3.5	6
35	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 356-61	2.8	3
34	Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior. <i>Stem Cell Research</i> , <b>2015</b> , 15, 109-21	1.6	49
33	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. <i>Journal of Pathology</i> , <b>2015</b> , 235, 593-605	9.4	20
32	Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma. <i>Cancer Science</i> , <b>2015</b> , 106, 34-42	6.9	12

31	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 430-6	4.4	8
30	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 423-9	4.4	13
29	Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. <i>Oncology Reports</i> , <b>2015</b> , 34, 1137-45	3.5	18
28	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 38789-803	3.3	104
27	A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e19039-e19039	2.2	
26	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 83, 37-43	5.9	68
25	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 85, 366-72	5.9	32
24	Eatenin contributes to lung tumor development induced by EGFR mutations. <i>Cancer Research</i> , <b>2014</b> , 74, 5891-902	10.1	60
23	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 83, 90-6	5.9	36
22	Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 248-53	8.9	11
21	The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. <i>Journal of Infection and Chemotherapy</i> , <b>2014</b> , 20, 356-60	2.2	3
20	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 216ra177	17.5	313
19	Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. <i>Molecular Cancer Research</i> , <b>2013</b> , 11, 759-67	6.6	155
18	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. <i>Molecular Medicine Reports</i> , <b>2013</b> , 8, 456-62	2.9	51
17	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology</i> , <b>2012</b> , 13, e23-31	21.7	401
16	Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. <i>Lung Cancer</i> , <b>2012</b> , 77, 31-7	5.9	29
15	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1086-90	8.9	124
14	Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. <i>Lung Cancer</i> , <b>2011</b> , 72, 32-8	5.9	17

13	The PCR-invader method (structure-specific 5'Qnuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. <i>International Journal of Clinical Oncology</i> , <b>2011</b> , 16, 335-44	4.2	43
12	A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 717-22	3.5	2
11	The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. <i>Molecular Cancer Research</i> , <b>2010</b> , 8, 1142-51	6.6	22
10	Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors. <i>International Journal of Oncology</i> , <b>2010</b> , 37, 1537-46	4.4	10
9	An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1096-103	8.9	38
8	Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. <i>Cancer Cell International</i> , <b>2008</b> , 8, 15	6.4	120
7	Small cystic insulinoma: value of arterial stimulation venous sampling. <i>CardioVascular and Interventional Radiology</i> , <b>1997</b> , 20, 308-10	2.7	6
6	Determination of Sulfoxazole. <i>Yakugaku Zasshi</i> , <b>1959</b> , 79, 113-115	0	
5	Studies on the Syntheses of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. I. <i>Yakugaku Zasshi</i> , <b>1959</b> , 79, 467-470	0	11
4	Studies on the Synthesis of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. II. <i>Yakugaku Zasshi</i> , <b>1959</b> , 79, 623-627	0	3
3	Studies on the Synthesis of 4, 5-Disubstituted Isoxazoles and their Cleavage Reaction with Sodium Ethoxide. III. <i>Yakugaku Zasshi</i> , <b>1959</b> , 79, 836-838	0	9
2	On the IronIII Complex Salt of Formyldeoxybenzoin. <i>Yakugaku Zasshi</i> , <b>1956</b> , 76, 655-656	0	
1	Studies on the Color Reaction of Fe+++ with Formyldeoxybenzoin. <i>Yakugaku Zasshi</i> , <b>1953</b> , 73, 185-187	0	2